BMT Tandem "Scientific" Meeting
Seaport Ballroom ABC (Manchester Grand Hyatt)
Chairs:
Steven M. Devine, MD
and
Jerome Ritz, MD
Disclosures:
S. M. Devine,
Nothing To Disclose
J. Ritz,
Biothera, Clinical Advisory Board member:
Advisory Board
Kiadis Pharma, Clinical Advisory Board member:
Advisory Board
A Survival Benefit for Reduced Intensity Allogeneic Transplants from Young Unrelated Donors Compared to Older Sibling Donors Depends on the Graft CD8 T-Cell Content
Ran Reshef, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Austin P. Huffman, BA, Perelman School of Medicine at the University of Pennsylvania;
Amy Gao, MS, Perelman School of Medicine at the University of Pennsylvania;
Mary Sell, BS MT, Perelman School of Medicine at the University of Pennsylvania;
Marlise R. Luskin, MD, Perelman School of Medicine at the University of Pennsylvania;
Selina Luger, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Alison Loren, MD, MS, Perelman School of Medicine at the University of Pennsylvania;
Elizabeth O. Hexner, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Sunita D. Nasta, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Noelle V. Frey, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Saar Gill, MBBS, PhD, Perelman School of Medicine at the University of Pennsylvania;
James Mangan, MD PhD, Perelman School of Medicine at the University of Pennsylvania;
Lee P Richman, BA, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania;
Taku Kambayashi, MD PhD, Perelman School of Medicine at the University of Pennsylvania;
Edward A. Stadtmauer, MD, Perelman School of Medicine at the University of Pennsylvania;
Robert H Vonderheide, MD DPhil, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania;
Rosemarie Mick, MS, Perelman School of Medicine at the University of Pennsylvania;
David L. Porter, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical Peripheral Blood CD34+ Cells (HaploCD34+) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection, and Frequent Pre-Engraftment Syndrome
Matias E Sanchez, MD, Memorial Sloan Kettering Cancer Center;
Doris M. Ponce, MD, Memorial Sloan Kettering Cancer Center;
Emily Lauer, BS, Memorial Sloan Kettering Cancer Center;
Marissa Lubin, BA, Memorial Sloan Kettering Cancer Center;
Jonathan Barone, BS, American Red Cross;
Courtney Byam, BS, Memorial Sloan Kettering Cancer Center;
Parastoo Dahi, MD, Memorial Sloan Kettering Cancer Center;
Richard Meagher, PhD, Memorial Sloan-Kettering Cancer Center;
Hugo Castro-Malaspina, M.D., Memorial Sloan Kettering Cancer Center;
Ann A. Jakubowski, PhD, MD, Memorial Sloan Kettering Cancer Center;
Guenther Koehne, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Esperanza Papadopoulos, MD, Memorial Sloan Kettering Cancer Center;
Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center;
Craig Sauter, MD, Memorial Sloan Kettering Cancer Center;
Roni Tamari, Memorial Sloan Kettering Cancer Center;
James W Young, MD, FACP, Memorial Sloan Kettering Cancer Center;
Andromachi Scaradavou, MD, Memorial Sloan Kettering Cancer Center;
Nancy A Kernan, MD, Memorial Sloan Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Richard J. O'Reilly, MD, Memorial Sloan Kettering Cancer Center;
Juliet Barker, MBBS (Hons) FRACP, Memorial Sloan Kettering Cancer Center
Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease (SCD)
Santosh Saraf, MD, University of Illinois at Chicago;
Annie Oh, MD, University of Illinois at Chicago;
Dolores Mahmud, PhD, University of Illinois at Chicago;
Karen Sweiss, PharmD, BCOP, University of Illinois at Chicago;
Pritesh Patel, MB, ChB, University of Illinois at Chicago;
Matthew Koshy, MD, University of Illinois at Chicago;
Sally Campbell-Lee, MD, University of Illinois at Chicago;
Nadim Mahmud, MD, PhD, University of Illinois at Chicago;
Victor Gordeuk, MD, University of Illinois at Chicago;
Damiano Rondelli, MD, University of Illinois at Chicago
Allogeneic Haematopoietic Stem Cell Transplantation for Systemic Onset Juvenile Idiopathic Arthiritis
Juliana Silva, MD, Great Ormond Street Hospital for Children NHS Trust;
Julie Glanville, Great Ormond Street Hospital for Children NHS Trust;
Fani Ladomenou, Great North Children's Hospital;
Rachael Hough, University College Hospital London;
Ben Carpenter, University College Hospital London;
Vicky Grandage, University College Hospital London;
Kanchan Rao, MD, MRCPCH, Great Ormond Street Hospital for Children NHS Trust;
Persis Amrolia, MD, PhD, Great Ormond Street Hospital for Children NHS Trust;
Robert Chiesa, MD, PhD, Great Ormond Street Hospital for Children;
Paul Brogan, Great Ormond Street Hospital;
Mark Friswell, Great North Children's Hospital;
Andrew J Cant, MD, Great North Children's Hospital;
Zohreh Nademi, Dr, Great North Children's Hospital;
Mary Slatter, MD, Great North Children's Hospital;
Mario Abinun, Great North Children's Hospital;
Paul Veys, MBBS, Great Ormond Street Hospital for Children
Induction of Durable Mixed Hematopoietic Chimerism and Immune Tolerance in Monkeys
Paula Alonso Guallart, D.V.M., Columbia University;
Jonah Zitsman, Columbia University;
Hugo Sondermeijer, M.D. M.S., Columbia University;
David Woodland, M.D., Columbia University;
Yojiro Kato, M.D., Columbia University;
Joshua Weiner, M.D., Columbia University;
Adam Griesemer, M.D., Columbia University;
Leo Bühler, M.D., Massachusetts General Hospital;
Alicia McMurchy, Ph.D., The University of British Columbia;
Megan Levings, Ph.D., The University of British Columbia | Child and Family Research Institute;
Megan Sykes, MD, Columbia University;
Raimon Duran-Struuck, D.V.M. Ph.D. DACLAM, Columbia University
Health-Related Quality of Life Among Older Adult Related Hematopoietic Stem Cells (HSC) Donors (>60 yrs.) Is Equivalent to or Better Than That of Younger Adult Related Donors (18-60 yrs.)
Galen E. Switzer, PhD, University of Pittsburgh;
Jessica G. Bruce, BA, University of Pittsburgh;
Deidre M. Kiefer, M.P.H., Center for International Blood and Marrow Transplant Research, National Marrow Donor Program;
Hati Kobusingye, MS, National Marrow Donor Program;
Rebecca J. Drexler, BS, AAS, National Marrow Donor Program;
RaeAnne M. Besser, BS, National Marrow Donor Program;
Roberta J. King, MPH, CIBMTR/National Marrow Donor Program;
Mary M. Horowitz, MD, MS, CIBMTR and Medical College of Wisconsin;
Dennis L. Confer, MD, National Marrow Donor Program;
Michael A. Pulsipher, MD, University of Utah School of Medicine
Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Philip A Thompson, MBBS, FRACP, FRCPA, The University of Texas MD Anderson Cancer Center;
Travis Perera, MBChB, FRACP, FRCPA, Royal Melbourne Hospital;
David Marin, The University of Texas MD Anderson Cancer Center;
Betul Oran, MD, The University of Texas MD Anderson Cancer Center;
Uday R. Popat, MD, UT MD Anderson Cancer Center;
Muzaffar H. Qazilbash, MD, The University of Texas MD Anderson Cancer Center;
Nina Shah, MD, The University of Texas MD Anderson Cancer Center;
Simrit Parmar, MD, The University of Texas MD Anderson Cancer Center;
Katy Rezvani, MD, The University of Texas MD Anderson Cancer Center;
Amanda Olson, M.D., The University of Texas MD Anderson Cancer Center;
Partow Kebriaei, MD, The University of Texas MD Anderson Cancer Center;
Gabriela Rondon, MD, The University of Texas MD Anderson Cancer Center;
Amin Alousi, MD, UT MD Anderson Cancer Center;
Stefan O. Ciurea, MD, The University of Texas MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Ashish Bajel, MBBS, Royal Melbourne Hospital;
Jeffrey Szer, MB, BS, FRACP, Royal Melbourne Hospital;
Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center;
David Stuart Ritchie, MBChB FRACP FRCPA PhD, Royal Melbourne Hospital;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center
Acceleration of Umbilical Cord Blood (UCB) Stem Engraftment: Results of a Phase I Clinical Trial with Stemregenin-1 (SR1) Expansion Culture
John E. Wagner, MD, University of Minnesota;
Claudio G. Brunstein, MD, PhD, University of Minnesota Medical Center;
David McKenna, MD, University of Minnesota;
Darin Sumstad, University of Minnesota Medical Center, Fairview;
Suzanne Maahs, PharmD, Novartis Institutes for BioMedical Research;
Mary J. Laughlin, MD, Global Program Medical Director Stem Cell Therapy Integrative Hospital Care Franchise, Novartis Pharmaceuticals Corp;
Michael S. Perry, DVM, PhD, FRCVS, Novartis Pharmaceuticals Corporation;
Anthony E. Boitano, PhD, Genomics Inst. of the Novartis Research Foundation;
Michael Cooke, PhD, Genomics Inst. of the Novartis Research Foundation;
Conrad C. Bleul, MD, Novartis Institutes for Biomedical Research, Translational Medicine ATI
![[Visit Client Website]](images/banner.gif)